The Effects of Heparin and Annexin V on Fibrin Accretion after Injury in the Jugular Veins of Rabbits

Summary

We compared the relative abilities of unfractionated heparin and annexin V to prevent fibrin accretion onto injured jugular veins in vivo. Heparin was used to accelerate the inhibition of thrombin by antithrombin III, and annexin V was used to inhibit the assembly of the prothrombinase complex on phospholipid surfaces, thereby blocking thrombin generation. Rabbit jugular veins were isolated in situ, a 2 cm segment was injured by perfusing it with air, and then blood flow was re-established. Five minutes later, each rabbit was injected with heparin (20 U/kg) or annexin V (0.3 mg/kg) and then with ¹²⁵I-fibrinogen. The amount of ¹²⁵I-fibrin accumulation onto each injured vessel wall segment was measured 4 h later. Each injured vessel was completely deendothelialized as a result of the air perfusion as demonstrated by electron microscopy. ¹²⁵I-fibrin accretion onto the injured jugular veins was enhanced 2.4-fold as compared to the uninjured veins in sham-operated animals. Heparin treatment did not reduce fibrin accretion, whereas, annexin V treatment decreased fibrin accretion by 60%, p <0.05. This latter effect was achieved without sustained circulating anticoagulation. Additional experiments confirmed that the inhibitory effect of annexin V on fibrin accretion was associated with a surface specific effect, since more annexin V bound to the injured jugular vein segments as compared to the non-injured jugular veins. We conclude that, i) mild vessel wall injury (selective de-endothelialization) in veins results in a thrombogenic vessel wall; ii) the thrombogenecity of which is not inhibited by prophylactic doses of heparin; but iii) is inhibited by annexin V, which binds to injured vessel wall surface, and inhibits thrombin generation independently of antithrombin III.

• References

• 1 Thomas DP. Pathogenesis of venous thrombosis. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds) Churchill Livingstone; Edinburgh: 1987: 767-778
• 2 Breddin HK. Thrombosis and Virchow’s Triad: What is established?. Semin Thromb Hemostas 1989; 15: 237-239
• 3 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574
• 4 Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1986; 89: 26S-35S
• 5 Boneu B, Buchanan MR, Cade JF, Van Ryn J, Fernandez F, Ofosu FA, Hirsh J. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo . Thromb Res 1985; 40: 81-89
• 6 Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. The effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo . Ann NY Acad Sci 1989; 556: 304-312
• 7 Brill-Edwards P, Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Antithrombin III independent thrombin inhibitors prevent thrombus growth more effectively than heparin: Implications for antithrombotic therapy. Thromb Haemostas 1991; 65: 785
• 8 Okwusidi J, Falcone M, Van Ryn-McKenna J, Hirsh J, Ofosu FA, Buchanan MR. In vivo catalysis of thrombin inhibition by antithrombin III and heparin cofactor II and antithrombotic effects: Differential effects of dermatan sulfate and unfractionated heparin. Thromb Haemorrh Disorders 1990; 1/2: 77-80
• 9 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. J Clin Invest 1989; 84: 1096-1104
• 10 Reutelingsperger CPM, Hornstra G, Hemker HC. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem 1986; 151: 625-629
• 11 Reutelingsperger CPM, Kop JMM, Hornstra G, Hemker HC. Purification and characterization of a novel protein from bovine aorta that inhibits coagulation. Eur J Biochem 1988; 73: 171-178
• 12 Regoeczi E. Fibrinogen catabolism: Kinetics of catabolism following sudden elevation of the pool with exogenous fibrinogen. Clin Sci 1970; 38: 111-121
• 13 Maurer-Fogy I, Reutelingsperger CPM, Pieters J, Bodo G, Stratowa C, Hauptmann R. Cloning and expression of cDNA for human vascular anticoagulant, a Ca²⁺-dependent phospholipid-binding protein. Eur J Biochem 1988; 174: 585-592
• 14 Buchanan MR, Richardson M, Haas TA, Hirsh J, Madri JA. The basement membrane underlying the vascular endothelium is not thrombogenic: In vivo and in vitro studies with rabbit and human tissue. Thromb Haemostas 1987; 58: 698-704
• 15 Hattersley PG. Activated coagulation time of whole blood. J Am Med Assoc 1966; 196: 436-440
• 16 Römisch J, Schorlemmer U, Fickenscher K, Pâques E-P, Heimburger N. Anticoagulant properties of placenta protein 4 (Annexin V). Thromb Res 1990; 60: 355-366
• 17 Dawson-Saunders B, Trapp RG. Comparing three or more means. In: Basic and Clinical Biostatistics. Appleton and Lange; Norwalk, CT: 1990: 124-141
• 18 Hatton MWC, Moar SL, Richardson M. Enhanced binding of fibrinogen by the subendothelium after treatment of the rabbit aorta with thrombin. J Lab Clin Med 115: 356-364
• 19 Van Ryn-McKenna J, Brill-Edwards P, Ofosu FA, Buchanan MR. Inhibition of thrombus growth is achieved more effectively by catalyzing thrombin inhibition by dermatan sulfate/heparin cofactor II than by heparin/antithrombin III. Thromb Haemostas 1991; 65: 785
• 20 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1104
• 21 Hauptmann R, Maurer-Fogy I, Krystek E, Bodo G, Andree H, Reutelingsperger CPM. Vascular anticoagulant ゲ a novel human Ca²⁺/phospholipid binding protein that inhibits coagulation and phospholipase A₂ activity. Eur J Biochem 1990; 185: 63-71
• 22 Andree HAM, Reutelingsperger CPM, Hauptmann R, Hemker HC, Hermens WT, Willems GM. Binding of vascular anticoagulant ケ (VACケ) to planar phospholipid bilayers. J Biol Chem 1990; 265: 4923-4928
• 23 Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1990; 264: 7944-7949